Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Konstantin Ichtchenko
New York University School of Medicine, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
CytoDel, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Ichtchenko’s work on the Grant uses an invention licensed to CytoDel, a company formed around a technology associated with genetically engineered botulinum toxins. The use of the invention is essential to accomplishing the Grant’s scope. Dr. Ichtchenko's significant financial interest is related to the PHS-funded research, and the Grant could have a significant impact on CytoDel’s business or financial outlook.
Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning.
PROJECT NARRATIVE: This project aims to develop novel botulism therapeutics based on the use of natural neuronal receptors and trafficking patterns normally employed by the targeted toxin itself. Unlike available antibody- based on atoxic derivatives of botulinum neurotoxin (BoNT) can reach an intracellular target in a post?exposure based therapeutics and small molecule inhibitors of the light chain metalloprotease, botulism therapeutics setting; unlike conventional, small molecule therapeutics which would equally affect all cells in the body with potentially deleterious cytotoxic side effects, the proposed atoxic BoNT-based molecular vehicle will specifically deliver a therapeutic moiety only to the cytosol of the target cells (motor neurons). This is a unique and innovative approach toward treating not only botulism, as embodied in this proposal, but also toward treating numerous infectious and neurodegenerative diseases in which therapeutic targets reside and exert their action intracellularly.
Filed on October 31, 2017.
Tell us what you know about Konstantin Ichtchenko's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Konstantin Ichtchenko filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Konstantin Ichtchenko | New York University School of Medicine | Conflict of Interest | CytoDel, LLC | $20,000 - $39,999 |
| Konstantin Ichtchenko | New York University School of Medicine | Conflict of Interest | CytoDel, LLC | $20,000 - $39,999 |
| Konstantin Ichtchenko | New York University School of Medicine | Conflict of Interest | CytoDel, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.